US 9,732,324 B2 · Anti-viral method

Abstract

The invention provides a method of reducing viral infectivity in a sample comprising contacting the sample with a earner matrix wherein lipids are attached to the carrier matrix, and wherein at least one virus-specific agent is attached to the lipids The virus-specific agent is capable of binding to at least one viral component The virus specific agent may be a receptor The earner matrix may be a silica particle, which may be coated with a lipid bilayer The invention further provides a method of inactivating a virus comprising contacting the virus with a earner matrix wherein lipids are attached to the earner matrix, and wherein at least one receptor is attached to the lipids, binding the receptor to at least one viral receptor-binding protein, and activating at least one viral fusion protein, wherein activation inactivates the virus, and releases the virus from the earner matrix.

Claims14

Dependent claims

A method of inactivating a Henipavirus comprising the steps of:

contacting the virus with a carrier matrix at 37° C., wherein lipids are attached to the carrier matrix, wherein at least one virus-specific cellular receptor is attached to the lipids, and wherein the cellular receptor is EphrinB2 (EFNB2);
binding the virus-specific cellular receptor to at least one viral receptor-binding protein at 37° C. to activate a viral fusion protein of the virus, thereby inactivating the virus without completing a fusion between the virus and the carrier matrix, wherein the viral receptor-binding protein is Henipavirus G protein, and wherein the viral fusion protein is Henipavirus F protein;
and
releasing the inactivated virus from the carrier matrix, wherein viral infectivity is reduced at least 50%.

1 more element

Dependencies are inferred from the claim text.

Anti-viral method

Life of this patent

Anti-viral method

Life of this patent

Abstract

Claims14